The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump

Core Viewpoint - The article discusses the negotiations between President Trump and CEO Albert Bourla, highlighting the complexities and dynamics involved in their discussions [1] Group 1 - The negotiations were described as a "long dance," indicating a prolonged and intricate process [1] - The involvement of high-profile figures such as President Trump and CEO Albert Bourla suggests significant implications for the industry [1]